Abstract

Objectives: In this study, we aimed to evaluate the performance of Endologix AFX® endografts in elderly in the early period and in the
first postoperative year.
Patients and methods: Between January 2012 and December 2017, a total of 63 consecutive patients (60 males, 3 females; mean age 68.2±7.2
years; range, 52 to 84 years) with an infrarenal abdominal aortic aneurysm (AAA) were operated using endovascular aneurysm repair
(EVAR) with an Endologix AFX® endograft in an elective fashion. The patients were divided into two groups as those aged under 70 years
(n=35) and over 70 years of age (n=28).
Results: The most associated comorbidities were hypertension (63.5%), coronary artery disease (57.1%), and chronic obstructive pulmonary
disease (38.1%). There was no 30-day mortality and no renal or cardiac morbidity in the early postoperative period. The mean length of
intensive care unit stay was 9±6.4 h and the mean length of hospital stay was 3±1.4 days, indicating no statistically significant difference
between the groups.
Conclusion: Our study results suggest that the Endologix AFX® endograft can yield successful outcomes in the early and postoperative first
year, irrespective of the age of the patient.

Key words: Early mortality; elderly patients; Endologix AFX endograft; endovascular aneurysm repair.